Skvarka Jan
- SEC CIK
- 0001838042
No open-market purchases or sales filed in the past year.
Current role at each company
- ZNTL Zentalis Pharmaceuticals, Inc.Directoras of Jun 18, 2026
- GLUE Monte Rosa Therapeutics, Inc.Directoras of Jun 12, 2026
- Trillium Therapeutics Inc.President and CEOas of Nov 19, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Skvarka Jan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ZNTL Zentalis Pharmaceuticals, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2025 (view filing) | Jan 31 | 4 days | Skvarka JanDirector | PPurchase | +60.0K | $1.72 | +$103.2K | +67.0%149.6K after | |
| Sep 13, 2023 (view filing) | Sep 11 | 2 days | Skvarka JanDirector | SSale | −5.00K | $25.05 | −$125.3K | −9.4%48.0K after | 10b5-1 |